StocktoriaCo-Diagnostics, Inc. CODX
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
1/9
Piotroski F — financial health
-16.26
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $622,489 | $3.9M | $6.8M | $34.2M | $97.9M |
| Gross profit | $400,112 | $2.9M | $2.6M | $28.7M | $86.3M |
| Operating income | -$50.2M | -$40.1M | -$42.7M | -$27.0M | $46.1M |
| Net income | -$46.9M | -$37.6M | -$35.3M | -$14.2M | $36.7M |
| Operating cash flow | -$29.1M | -$29.2M | -$22.1M | $6.6M | $41.1M |
| Free cash flow | -$29.8M | -$29.9M | -$23.4M | $5.1M | $40.4M |
| Total assets | $24.7M | $63.6M | $95.3M | $123.1M | $160.0M |
| Total liabilities | $4.1M | $9.7M | $9.3M | $8.6M | $25.6M |
| Shareholders' equity | $20.6M | $53.9M | $85.6M | $114.5M | $134.5M |
| Ratios | |||||
| Gross margin | 64.3% | 74.5% | 38.6% | 84.0% | 88.2% |
| Operating margin | -8058.8% | -1023.7% | -626.9% | -78.8% | 47.1% |
| Net margin | -7533.6% | -961.4% | -518.7% | -41.6% | 37.5% |
| FCF margin | -4793.2% | -763.8% | -344.2% | 15.0% | 41.3% |
| Return on assets | -189.5% | -59.2% | -37.1% | -11.6% | 22.9% |
| Return on equity | -227.3% | -69.9% | -41.3% | -12.4% | 27.3% |
| Current ratio | 3.87 | 4.41 | 10.81 | 23.94 | 9.14 |
| Revenue growth | -84.1% | -42.5% | -80.1% | -65.0% | 31.3% |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -16.26 (distress)
- Working capital / assets 0.41
- Retained earnings / assets -3.248
- EBIT / assets -2.027
- Equity / liabilities 5.014
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001692415 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.